BCMA-Directed CAR T-Cell Therapy Shows Promise for Durable, Drug-Free Remission in Refractory Primary Immune Thrombocytopenia
A first-in-human study demonstrates that BCMA-targeted CAR T-cell therapy induces rapid, sustained platelet recovery and durable drug-free remission in refractory primary immune thrombocytopenia with manageable safety.